Trucap FDA-Approved for HR +ve and HER2 -ve Breast Cancer

Author: owner     Published: 7 months ago 0 Replies

TRUQAP, along with fulvestrant, is used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced, or metastatic breast cancer.

This is specifically for patients who have alterations in PIK3CA/AKT1/PTEN, identified by an FDA-approved test.

This treatment is recommended after progression on at least one endocrine-based regimen in the metastatic setting or recurrence within 12 months of completing adjuvant therapy.

Capivasertib is a medicine that blocks three forms of a protein called AKT, which is involved in cell processes.

It stops the activation of AKT and its effects on other substances in the body.

In tumors, AKT gets activated due to various reasons like mutations in AKT1, problems with PTEN function, or mutations in PIK3CA.

Capivasertib was tested in the lab (in vitro) and it slowed down the growth of breast cancer cells, especially those with certain mutations. In live tests (in vivo), capivasertib, by itself and with fulvestrant, slowed down the growth of tumors in mice, specifically those with estrogen receptor positive breast cancer and alterations in PIK3CA, AKT1, and PTEN.

Login to Reply

Money Back Guarantee
We return Money in 24 Hours

Secure online payment
We possess SSL / Secure Certificate

12/7 customer support
Well-trained & Supportive team

PMDC Verified Doctors
Authentic & updated information

Book Online and In-clinic appointment with your doctor. Consult via Video chat and get a prescription. Ask any question in the "Forum" section and get a detailed answer. Discuss your health issues.

Connect with us

Copyright @ 2024 - All Rights Reserved Reproduction of material from any pages without permission is strictly prohibited.